Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FRDK0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,629
Award facts
- Contract value 100% obligated
- $17,628.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,628.86 to DMS Pharmaceutical Group Inc. for Cabometyx 40 mg tablets (30-count units) on January 5, 2026, with an ultimate completion date of January 6, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supporting Department of Defense pharmaceutical supply needs globally.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance across the PPV-G GEN V platform, supplying a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and specialty products to military healthcare facilities. The underlying PPV-G GEN V contract, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. This delivery order for Cabometyx, an oncology treatment, reflects the company's role in fulfilling the specialized pharmaceutical requirements of the Department of Defense's medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FRDK0?
SPE2DR26FRDK0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FRDK0 worth?
The government has obligated $17,629 on SPE2DR26FRDK0.
Is contract SPE2DR26FRDK0 an order under another contract?
Yes. SPE2DR26FRDK0 is a delivery order under SPE2DR25D9143, an indefinite delivery contract.
Was contract SPE2DR26FRDK0 competed?
The extent of competition for SPE2DR26FRDK0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award